Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational  Study.

CONCLUSION: In real life, ponatinib is a "niche-drug" reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates. PMID: 29773429 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

This study proposed a pilot study of a new tool for a reliable and accurate stratification of patients with acute leukemia based on an integrative model of leukemia behavior, cell characterization, and clinical features, in addition, to an evaluation of intra-tumor and inter-tumor heterogeneity. Together our approach allows us to introduce an integrative quantitative approach to use zebrafish and tumor characterization as a prediction tool for the behavior of acute leukemia in young adults. Materials and Methods Animal Care and Handling Zebrafish wild-type (A/B and TAB5) adults were raised and maintained according to st...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Immunotherapy is a promising approach to improve treatment responses in hematological malignancies. Accumulating evidence suggests a role for natural killer (NK) cells in controlling hematological malignancies. However, mechanisms regulating sensitivity or resistance of hematologic cancer cells to the effector function of NK cells are incompletely understood. Here, we performed genome-scale CRISPR-Cas9 loss-of-function screens to systematically map genes that regulate sensitivity of hematologic malignancies to NK cells.To screen for genes involved in the interaction between NK and cancer cells, we infected human cancer cel...
Source: Blood - Category: Hematology Authors: Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Pre-clinical T and NK Cell Immunotherapies Source Type: research
Conclusion: This study has established the responsiveness and MCID for both Part A and Part B of HM-PRO. The HM-PRO is capable of detecting small but clinically important changes in patients' HRQoL over time. The MCID for Part A based on SEM was 6.2 and for PART B 5.9 points. It would therefore be prudent, for practical reasons, to propose a MCID of '6' for the HM-PRO.DisclosuresOliva: Sanofi: Consultancy, Speakers Bureau; La Jolla: Consultancy; Amgen: Consultancy, Speakers Bureau; Celgene: Consultancy, Other: Royalties, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau. Ionova:...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research
Conclusion: This study employed the anchor-based approach for devising a set of score banding for both Part A and Part B of HM-PRO. The proposed bands (Part A=0-7, 8-25, 26-41, 42-74, 75-100; Part B=0-3, 4-16, 17-29, 30-65, 66-100) had the highest agreement and number of patients in the individual bands. The proposed bands could be applied independent of gender and different age groups. The findings of this study will help the clinician and the care team to interpret the HM-PRO scores to aid their clinical decision-making process in daily routine practice.DisclosuresOliva: Sanofi: Consultancy, Speakers Bureau; Celgene: Con...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research
Objective: To investigate the clinical features of 2nd hematological malignancies post to the initial cancer treatment.METHODS: A retrospective study was performed to analyze the available clinical data of 116 patients diagnosed with 2nd hematologic malignancies after treatment of various malignant tumors from June 1998 to June 2018 at Sun Yat-sen University cancer center.RESULTS: The characteristics of the 116 patients diagnosed with 2nd hematological cancer post to initial cancer treatment were indicated as following: 62 males and 54 females. The primary tumor category was grouped as (according to ICD-10 International Di...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions Source Type: research
ConclusionIn real life, ponatinib is a “niche-drug” reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Primary chemotherapy drug resistance is a one of the major issues of medical hematology-oncology affecting about 20% of all patients. In Armenia, clinical data suggest that the rate of primary resistance depends on the disease and treatment type and varies in the range of 10-30%. One of the mechanisms of resistance is a drug inactivation mediated by metabolizing enzymes and it has been known that the variability of those genes contributes to the response to drugs and treatment efficacy. In Armenia a number of drugs are used for treatment acute and chronic hematology-oncological diseases, such as doxorubicin and vincristine...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Ponatinib is an oral tyrosine kinase inhibitor (TKI) that potently inhibits BCR-ABL1 and is approved in the US for the treatment of patients with CML or Ph+ ALL for whom no other TKI is indicated, or those with the T315I mutation. Long-term follow up of the pivotal PACE study (NCT01207440) showed a higher cumulative incidence of vascular occlusive events (VOEs) than reported at the time of ponatinib approval. Dose reductions were therefore implemented within PACE to mitigate the risk of VOEs. The exposure-adjusted incidence of VOEs has not increased over time in PACE but was greater in patients with a history of risk factors.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusions The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease. Prospective studies are warranted.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with high-risk hematologic malignancies [1,2]. Common indications for HCT in adults include acute myelogenous leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, lymphoma, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and certain solid tumors [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Israel Health | Leukemia | Lymphoma | Middle East Health | Myeloma | Study